280 related articles for article (PubMed ID: 29662921)
1. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.
Holden SK; Finseth T; Sillau SH; Berman BD
Mov Disord Clin Pract; 2018; 5(1):47-53. PubMed ID: 29662921
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale in Two Independent Cohorts with Early Parkinson's Disease.
Bartl M; Dakna M; Schade S; Wicke T; Lang E; Ebentheuer J; Weber S; Trenkwalder C; Mollenhauer B
J Parkinsons Dis; 2022; 12(1):437-452. PubMed ID: 34719511
[TBL] [Abstract][Full Text] [Related]
3. Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.
Evers LJW; Krijthe JH; Meinders MJ; Bloem BR; Heskes TM
Mov Disord; 2019 Oct; 34(10):1480-1487. PubMed ID: 31291488
[TBL] [Abstract][Full Text] [Related]
4. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
[TBL] [Abstract][Full Text] [Related]
5. The effect of cardiovascular risk on disease progression in
Oosterwegel MJ; Krijthe JH; den Brok MGHE; van den Heuvel L; Richard E; Heskes T; Bloem BR; Evers LJW
Front Neurol; 2023; 14():1138546. PubMed ID: 37122316
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.
Simuni T; Siderowf A; Lasch S; Coffey CS; Caspell-Garcia C; Jennings D; Tanner CM; Trojanowski JQ; Shaw LM; Seibyl J; Schuff N; Singleton A; Kieburtz K; Toga AW; Mollenhauer B; Galasko D; Chahine LM; Weintraub D; Foroud T; Tosun D; Poston K; Arnedo V; Frasier M; Sherer T; Chowdhury S; Marek K;
Mov Disord; 2018 May; 33(5):771-782. PubMed ID: 29572948
[TBL] [Abstract][Full Text] [Related]
7. Predicting the Progression of Parkinson's Disease MDS-UPDRS-III Motor Severity Score from Gait Data using Deep Learning.
Zia Ur Rehman R; Rochester L; Yarnall AJ; Del Din S
Annu Int Conf IEEE Eng Med Biol Soc; 2021 Nov; 2021():249-252. PubMed ID: 34891283
[TBL] [Abstract][Full Text] [Related]
8. Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study.
Ueno T; Kon T; Haga R; Nishijima H; Arai A; Tomiyama M
Neurol Sci; 2020 Oct; 41(10):2867-2873. PubMed ID: 32328832
[TBL] [Abstract][Full Text] [Related]
9. Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
ZhuParris A; Thijssen E; Elzinga WO; Makai-Bölöni S; Kraaij W; Groeneveld GJ; Doll RJ
Mov Disord; 2023 Oct; 38(10):1795-1805. PubMed ID: 37401265
[TBL] [Abstract][Full Text] [Related]
10. Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
van den Heuvel L; Evers LJW; Meinders MJ; Post B; Stiggelbout AM; Heskes TM; Bloem BR; Krijthe JH
Mov Disord; 2021 Feb; 36(2):407-414. PubMed ID: 33107639
[TBL] [Abstract][Full Text] [Related]
11. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
[TBL] [Abstract][Full Text] [Related]
12. Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales.
Gottipati G; Berges AC; Yang S; Chen C; Karlsson MO; Plan EL
Pharm Res; 2019 Jul; 36(9):135. PubMed ID: 31317279
[TBL] [Abstract][Full Text] [Related]
13. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores.
Goetz CG; Stebbins GT; Tilley BC
Mov Disord; 2012 Sep; 27(10):1239-42. PubMed ID: 22886777
[TBL] [Abstract][Full Text] [Related]
14. Lateralization of Motor Signs Affects Symptom Progression in Parkinson Disease.
Elkurd M; Wang J; Dewey RB
Front Neurol; 2021; 12():711045. PubMed ID: 34385975
[No Abstract] [Full Text] [Related]
15. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Goetz CG; Tilley BC; Shaftman SR; Stebbins GT; Fahn S; Martinez-Martin P; Poewe W; Sampaio C; Stern MB; Dodel R; Dubois B; Holloway R; Jankovic J; Kulisevsky J; Lang AE; Lees A; Leurgans S; LeWitt PA; Nyenhuis D; Olanow CW; Rascol O; Schrag A; Teresi JA; van Hilten JJ; LaPelle N;
Mov Disord; 2008 Nov; 23(15):2129-70. PubMed ID: 19025984
[TBL] [Abstract][Full Text] [Related]
16. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
[TBL] [Abstract][Full Text] [Related]
17. Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST.
Watanabe H; Saiki H; Chiu SW; Yamaguchi T; Kashihara K; Tsuboi Y; Nomoto M; Hattori N; Maeda T; Shimo Y;
Mov Disord Clin Pract; 2020 May; 7(4):431-439. PubMed ID: 32373660
[TBL] [Abstract][Full Text] [Related]
18. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.
Skorvanek M; Martinez-Martin P; Kovacs N; Rodriguez-Violante M; Corvol JC; Taba P; Seppi K; Levin O; Schrag A; Foltynie T; Alvarez-Sanchez M; Arakaki T; Aschermann Z; Aviles-Olmos I; Benchetrit E; Benoit C; Bergareche-Yarza A; Cervantes-Arriaga A; Chade A; Cormier F; Datieva V; Gallagher DA; Garretto N; Gdovinova Z; Gershanik O; Grofik M; Han V; Huang J; Kadastik-Eerme L; Kurtis MM; Mangone G; Martinez-Castrillo JC; Mendoza-Rodriguez A; Minar M; Moore HP; Muldmaa M; Mueller C; Pinter B; Poewe W; Rallmann K; Reiter E; Rodriguez-Blazquez C; Singer C; Tilley BC; Valkovic P; Goetz CG; Stebbins GT
Mov Disord Clin Pract; 2017; 4(4):536-544. PubMed ID: 30363418
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
Front Neurol; 2021; 12():705407. PubMed ID: 34659081
[No Abstract] [Full Text] [Related]
20. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
